Dysfunction of cell-cycle checkpoints in DNA mismatch repair (MMR)-deficient cells in response to DNA damage has implications for anticancer therapy and genetic instability. We have studied the cell-cycle effects of MMR deficiency (Msh2
Introduction
The cellular DNA mismatch repair (MMR) pathway, detects and repairs DNA frame shifts, replication errors and regulates recombination events (Kolodner, 1995) . The pathway requires the assembly of MMR protein complexes at mismatch sites, followed by exonuclease action and resynthesis (Karran and Bignami, 1999) . In humans, the damage recognition steps are through the hMutS-alpha (hMsh2/hMsh6) or the hMutSbeta (hMsh2/hMsh3) complexes that subsequently act to recruit other proteins. MMR abnormalities are characterized by a mutation of one of the genes whose products are normally involved in this repair pathway (hMSH2, hMLH1, hPMS1, or hPMS2; Buermeyer et al., 1999) . Loss of MMR causes destabilization of the genome and results in high mutation rates (Buermeyer et al., 1999) . It is known that dysfunction of MMR increases the risk of cancer in families with hereditary nonpolyposis colon carcinoma, and it is also common in many types of sporadic human cancers. In mammalian cells, the loss of cell-cycle checkpoints has also been linked with genetic instability and cancer formation (Hartwell and Kastan, 1994) . However, the extent to which putative MMR-associated defects in checkpoint control can contribute to genetic instability in nontumour cell populations is not clear. Here we report on the temporal dissection of the premitotic cell-cycle delays, induced by the DNA-damaging agent cisplatin, in early passage mouse embryonic fibroblasts (MEFs) to determine the discrete effect of Msh2 deficiency.
The effects of MMR loss on cellular responses to DNA damage are complex. MMR deficiency results in resistance to several chemotherapeutic agents by impairing the ability of the cell to detect drug-induced intrastrand adducts that mimic base mismatches (Fink et al., 1998) . Consequently, the MMR defective cell no longer triggers cell death at the normal rate after exposure to drugs such as 6-thioguanine, N-methyl-N 0 -nitro-N-nitrosoguanidine, carboplatin or cisplatin, therefore providing the potential to accrue further mutations (Fishel et al., 1993; Toft et al., 1999) . Melanoma cells exhibiting resistance to cisplatin show reduced nuclear levels of MMR proteins hMLH1, hMSH2 and hMSH6 (Lage et al., 1999) . In contrast, de las Alas et al. (1997) found no difference in the mutation rates of MMR-proficient and -deficient cells after cisplatin exposure in human colon cancer cell cultures as did Lin et al. (2001) . Sansom et al. (2001) found that Msh2 À/À deficient mouse intestinal cells treated with cisplatin in vivo showed a reduction in cell death and no significant elevation of mutation frequencies.
The repair system is involved in promoting damageinduced G2 cell-cycle arrest (Brown et al., 1997; Moreland et al., 1999) . It has been proposed that such G2 arrest is essential to the process of engaging cell death after cisplatin treatment (Sorenson and Eastman, 1988; Evans and Dive, 1993; Kravtsov et al., 1999) .
Thus, it seems likely that the premature commitment of Msh2 À/À cells carrying induced DNA damage to cell division, without an attendant triggering of cell death, may constitute a route to aneuploidy and genetic variation.
Two molecularly distinct G2 checkpoints associated with DNA damage induced by ionizing irradiation (IR) have been identified (Xu et al., 2002) . The first of these G2 checkpoints occurs early after IR, is very transient, ATM-dependent (Xu et al., 2001 ) and relatively doseindependent. This early-acting checkpoint represents the failure of cells, which had been in G2 at the time of irradiation, to progress into mitosis. Cell-cycle progression assays that can distinguish mitotic cells from G2 cells, such as time-lapse microscopy, must be used to assess this transient arrest. In contrast, G2/M accumulation, typically determined by DNA-dye staining, essentially comprises cells that had been in earlier phases of the cell cycle at the time of exposure to the DNA-damaging agent and is measurable only after several hours. This late-activating checkpoint is ATM-independent and dose-dependent. G2/M accumulation after IR is not affected by the early G2 checkpoint (Xu et al., 2002) . We hypothesized that a two-component G2 response may also occur in cisplatin-treated MEFs and that MMR deficiency my have a selective impact.
Most of the studies on the role of MMR have been performed in tumour-derived or immortalized cell cultures. Such cell lines often harbour ill-defined alterations in cell-cycle control (Zindy et al., 1998 ) that could mask the full impact of a discrete MMR deficiency on cell-cycle arrest (Strathdee et al., 2001 ) and its implications for genetic instability. Here we have used MEFs in which one of the MMR proteins, Msh2, has been genetically inactivated. Despite the elegance of the MEF cultures in presenting near-normal phenotypes, the system presents significant problems for cell-cycle perturbation studies. These include variations due to different source embryos and the progressive loss of proliferative potential during the early passages of in vitro culture. The current study accounts for such complicating factors by the use of multivariate Cox regression, establishing a model system that is robust enough for discerning the functional checkpoint status of Msh2 À/À MEFs. Time-lapse microscopy provides a means of independently tracking the responses of minority but highly informative subpopulations. The nonperturbing approach permits the linking for the first time in the MMR-MEF system events such as mitotic entry, with G2 checkpoint breaching, together with mitotic delay and catastrophe.
Materials and methods

Cell isolation and culture
Wt and Msh2
À/À MEFs were derived from 13-day-old embryos derived from an outbred colony segregating for C57B1/6 (93.5%) and Ola129 (6.5%) genomes, using standard methods (Strathdee et al., 2001) . After 3 days in culture, the MEFs were frozen down in 10% DMSO/FCS solution. When in culture, cells were maintained in BHK-21 medium, containing 10% foetal bovine serum supplemented with penicillin and streptomycin, and grown in an atmosphere containing 5% CO 2 . Cells were plated at a density of 2 Â 10 4 cells/ml (volumes of 1 ml/ well in 24-well plates, and 4 ml/well in six-well plates) 24 h before experiments.
Drug treatment
Stock cisplatin solutions (1 mg/ml, Faulding Pharmaceuticals Plc, UK) were kept at room temperature. Appropriate dilutions were added to culture wells to obtain treatment conditions of 0, 5 or 10 mM of cisplatin. After 1 h at 371C, the cultures were washed twice with warmed fresh medium and incubation continued.
Flow cytometry
Cells grown in six-well dishes were used for cell-cycle analysis. At 24 h post-treatment, the cells were trypsinized, permeabilized and ethidium bromide stained as described previously (Epstein et al., 1988) . The preparations were analysed using a Becton-Dickinson FACscalibur flow cytometer and the results analysed using the algorithm described by Watson et al. (1987) for cell-cycle phase quantification.
Time-lapse microscopy: acquisition and analysis
Immediately post-treatment, the cultured dishes were placed onto a time-lapse instrument designed to capture transmissionphase images from multiwell plates. An Axiovert 100 microscope (Carl Zeiss, Welwyn Garden City, UK) was fitted with an incubator for 371C/5% CO 2 maintenance (Solent Scientific, Portsmouth, UK), and an ORCA-ER CCD camera (Hamamatsu, Reading, UK). Illumination was controlled by a shutter in front of the transmission lamp, and an x, y positioning stage with separate z-focus (Prior Scientific, Cambridge, UK) controlled multi-field acquisition. Image capture was controlled by AQM 2000 software (Kinetic Imaging Ltd). All images were collected with a Â 10 (PH1) apochromat objective lens providing a field size of 500 Â 500 mm 2 . Sequences were captured over 24 h, every 10 min, and for three fields per treatment regime.
The analysis of the images was performed with the integrated AQM 2000 software package (Kinetic Imaging). Each cell in the field was tracked individually and the time to mitosis or death was recorded. The outcome of the mitosis was classified as a daughter event (when a successful mitosis occurred; Figure 1aI , b), a polyploid event (when no segregation occurred; Figure 1aII , b), or cell death (the cell shrinks, blebs and disintegrates) (Figure 1aIII , b). The duration of the time to resolve an outcome from a round/ refractile cell to resolution was also measured.
The 'time-to-event' data were processed and presented in plots, representing the dynamics of cumulative events occurring in a treatment regime, so that quantitative comparisons from well to well were possible. The plot of cumulative events over time ( Figure 1c ) provides a basic graphical display. However, normalizing this against the number of cells (or the potential for events) in the original field derives a 'cumulative event potential' parameter, enabling quantitative comparisons of drug effects ( Figure 1d ). Finally, normalizing the cumulative event potential of the controls to represent 100% at 24 h enabled the pooling of independently derived cultures and the comparison of event curves for two different cultures with different genetic backgrounds (Wt and Msh2
À/À
).
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Statistics
Cox regression and log-rank methods were used to analyse the time to a given end point. The use of Cox regression allowed the effect of the variation between cell lines to be included in the model and, in general, a stratified analysis was performed in order to test the effect of drug within a given cell line. Cells that moved out of the field during the period of observation, and those that did not divide or die, were considered to be censored at a given time point. Data were analysed using the survival library in S-Plus 2000 (Therneau and Grambsch, 2000) .
Results
Cell-cycle perturbations induced by cisplatin of Wt and Msh2
À/À cells
To assess the wider cell-cycle effects of cisplatin on Wt and Msh2 À/À cells, cultures were exposed for 1 h to 0, 5 and 10 mm of cisplatin, and then analysed 24 h posttreatment using flow cytometry. Colcemid exposure was used to assess first cycle traverse capacity by capturing cells at the spindle-assembly checkpoint.
In Table 1 the population cell-cycle perturbation of the MMR-deficient and -proficient cells after the different treatment regimes is shown. Cisplatin resulted in an accumulation of cells in G2/M in both Wt-and Msh2 À/À -derived populations. At both dose levels, the Wt population demonstrated an apparently greater arrest than its Msh2 À/À counterpart. Colcemid trapping in late G2 and mitosis showed that the majority of cells from both cultures were cycling, although Msh2 À/À had a higher traverse rate, and this was reflected in the growth rate for the corresponding cultures (Figure 2) . The results for cisplatin treatment combined with colcemid did not differ from those for colcemid alone (data not shown) for either cell type, suggesting that cisplatin did not affect cell-cycle progress pre-G2/M. A low percentage of polyploids were detected in both nontreated cell cultures (3.2% for the Wt and 1.6% for Msh2 À/À ). The arrest produced by cisplatin was corrected for the overall proliferation potential of cells available (i.e. 26.6% in Wt cells and 46.2% in Msh2 À/À ). After correcting the net accumulation for overall trapping potential, the data revealed that both cell types show a G2 arrest after cisplatin treatment, although this was reduced in Msh2-deficient cells. This effect of cisplatin on Msh2-deficient MEFs corroborate previous studies (Strathdee et al., 2001) .
Assay performance for screening cisplatin effects on MEF cultures
Our data showed that both Wt and Msh2 À/À cultures responded with G2 arrest after the treatment with cisplatin, although we found that this response was more pronounced in the Wt-derived cells (Table 1) . The apparent discrepancy with previous reports for cisplatin effects on MEF cultures (Strathdee et al., 2001 ) may arise from the inherent problems of preparing cells from embryos with vastly different growth characteristics.
For that reason, we sought to develop a robust protocol, starting from the cell isolation procedures through to the methods for single cell image analysis, to provide an MEF model, informative for high-resolution checkpoint screening. The time-lapse microscopy-based assay provides high temporal resolution of responses at the single cell level. The event curve is derived from measuring cumulative time to mitosis of individual cells, each contributing to a kinetic picture of the population response. Figure 1 provides examples of typical outcomes from the event analysis and how subsequently the kinetics of single cell responses were reduced for quantitative presentation. Significantly, in postdrug Msh2 and G2-M transition N Marquez et al treatments no gross abnormal morphological or motility changes were observed. Cell preparations derived from different embryos showed variation in growth rates (Figure 3c ) contributing 'noise' to the assay. Each culture has an event potential that is equivalent to the number of cells in each field. We ascertained for practical reasons that at least 50% of the cells had to participate in the assay these are an informative cells. The effect of passage (Figure 3a and c) proved to be considerable, since in the regression model there was a highly significant reduction in the rate of cell division in passage 3 and 4 when compared to passage 2 (P50.001). Therefore, passage 2 (with a event potential range of 49-61%) proved to be the most appropriate time for these assays and hence requiring only 80 cells in total for each treatment regime. Different wild-type embryos in passage 2 showed a statistically significant difference (Cox model (P50.001)) in cumulative event potential over 24 h (Figure 3d ), varying from 105 to 48%.
Time-lapse analysis reveals reduced mitotic potential after cisplatin treatment
Wt and Msh2
À/À cultures were treated with either 0 or 10 mm of cisplatin and followed by digital time-lapse microscopy for 24 h. The cumulated event potential at 24 h was calculated according to the procedure given in Materials and Methods and as shown in Figure 1d . Cisplatin treatment reduced the overall delivery of cell to mitosis in both Wt and Msh2 À/À cells (Cox model, P50.001; Figure 4 ). The abrogation of delivery to mitosis resulted in a reduction from 56 to 32% (Wt; 1.7-fold reduction) and 40 to 24% for Msh2 À/À (1.6-fold reduction). There was a background of polyploid outcomes (4 and 6% for Wt and Msh2
À/À
, respectively) and cell death (2 and 0% for Wt and Msh2 À/À , respectively), which was not significantly altered after drug treatment. This trend was confirmed after performing the same analysis in several cell cultures derived from other individuals. Cisplatin, therefore, showed a profound first cycle effect that can be categorized as cytostatic rather than cytotoxic in the present study.
We found that different Wt cultures after treatment showed similar kinetics, regardless of their culture Cells were exposed to 0, 5 or 10 mm of cisplatin for 1 h, or 0.5 mg/ml colcemid for 24 h. a Net G2/M increase of treated cells was calculated by subtracting the corresponding G2/M control.
b Then, the percentage of potential G2/M trapped cells were calculated (net G2/M increase over net increase of colcemid treated cells)
Figure 2 Growth curves represented as cumulative population doublings of Msh2
À/À and Wt cultures. These are the same cultures used for the flow cytometric analysis (Table 1) with an arrow indicating the point at which the cultures were used for analysis (passage 2) Objective comparisons were made between the MMRproficient and -deficient cell cultures by pooling nine timelapse microscopy data sets for five Wt cell cultures, and five Msh2 À/À , in passage 2, with and without treatment for 1 h with 10 mm cisplatin. Then we normalized the accumulative number of events to the final percentage of cells that were informative after 24 h (Figure 6a) .
The data showed a small (though significant) difference between Msh2 À/À and Wt cultures in their overall response to cisplatin treatment. After 24 h of the drug treatment, the abrogation in the normalized cumulative events was only marginally greater (13%) in the proficient MMR cells compared to the deficient culture (Figure 6a ). However, for the first 5 h of the event curve, we can assign original cell-cycle position to these cells, since the first cohort to deliver to mitosis must be in G2 during the drug treatment. Dissection of the rates of delivery to mitosis in this subfraction shows that the difference in the response to cisplatin between Wt and Msh2 À/À is due largely to a reduction in G2 delay observed in drug-treated Msh2 À/À cells within the first 5 h after treatment. In untreated cells, in the first 5 h post-treatment, both Wt and Msh2 À/À cultures showed a cumulative event potential of 22% (Figure 6b, c) . Upon treatment with 10 mm cisplatin, the Msh2 À/À G2 cells progressed unaffected by the drug treatment (Figure 6c) , while the Wt-treated G2 cells were immediately slowed in their ability to deliver to mitosis (Figure 6b ). During this period, the rate of delivery in Wt cultures was reduced approximately 1.5-fold, leading to an 8% reduction in cumulative events. Cox regression analysis indicated that this effect due to cisplatin was significant in Wt cells (P ¼ 0.046) but not in Msh2 À/À (P ¼ 0.58). Subsequently, for the next 5-h period (5-10 h posttreatment), Msh2
À/À cells started to reveal a druginduced reduced rate of delivery to event similar to the Wt cultures (Figure 6d,e) .
To assess whether premature commitment to mitosis in Msh2 À/À cells or checkpoint breaching at later times resulted in mitotic catastrophe or delay, event duration, defined as the time elapsed from cell rounding to resolution, was also recorded. The resolution of this measurement is 75 min. . The difference between these four mean durations is not significant (two-way AVOVA, P40.05); therefore, although the rate of commitment to mitosis was affected by cisplatin, the process of cytokinesis itself was left unperturbed.
Discussion
We have used time-lapse microscopy to clarify the role of Msh2 in the early and sustained effects of an acute expose to the DNA-damaging agent cisplatin. The MEF model system was evaluated and optimized to account for the background factors and ensure that perturbations resulting from drug treatment were quantifiable. We report on the effective loss of the earlyacting G2 damage-activated checkpoint in Msh2
MEFs. The duration of mitosis and its outcome for Msh2 À/À cells committed to cell division following cisplatin exposure are similar to the untreated controls. The results provide an insight into the impact of Msh2 loss on cell responses to DNA damage and suggest that Msh2-driven MMR-dependent processes are normally rapidly engaged in triggering arrest signals. Our single cell analysis approach overcomes the clear problem of relatively infrequent informative cells, a problem that severely compromises population-based cellular and molecular analyses.
MMR appears to play an important role in the stress physiology of the cell, functioning as a detector of DNA damage that activates other cell-cycle regulators such as p53, p73 or c-abl (Bellacosa, 2001 ). An early role for MMR in the cell-cycle arrest process is suggested by our findings. This would be consistent with a post-translational regulation of MMR in the primary and perhaps early response of cells to genotoxic stress. Accordingly, the MutS-alpha complex can undergo phosphorylation in the cell, while the lack of MSH2 and MSH6 phosphorylation in vivo significantly reduces mismatchbinding activity of MutS-alpha and prevents methylation-induced nuclear translocation of the repair complex from the cytoplasm (Christmann and Kaina, 2000; Christmann et al., 2002) .
Our initial flow cytometric analysis of Wt and Msh2
À/À cells treated with cisplatin showed a similar G2 arrest, albeit greater in the Wt. However, if we take into account the percentage of cells potentially available for registering arrest (estimated from the number of cells trapped in G2 after 24 h colcemid treatment), then the arrest for the Wt is 3-4.5-fold greater in the normal compared with knockout cultures. This is in concordance with other authors, where MMR-deficient cells have shown a reduced G2 arrest after being treated with cisplatin (Brown et al., 1997; Lin et al., 2001) . MEFs represent a model with relatively unaltered mechanisms compared with the multiple abnormalities evident in tumour cell lines. Using these cells, Strathdee et al. (2001) showed that Msh2
-deficient cells could perform a G2 arrest after being treated with cisplatin, although this study lacked the temporal resolution reported here. We have shown that the medium term (o24 h) effect of an acute exposure to cisplatin is an arrest of the culture, without a significant elevation in the frequency of cell death, abnormal polyploid cells or the duration of mitosis.
The current results may have new implications for drug resistance to cisplatin. We have shown that MMRdeficient cells display a specifically derived resistant phenotype at the early-acting G2 checkpoint. Therefore, understanding this enables the design of drug regimens that take this into account, such as combination treatment with mitotic disrupters. It could also offer an explanation for the low levels of cisplatin resistance in Msh2-deficient cells (Fink et al., 1996; Aebi et al., 1997; de las Alas et al., 1997) . Methylating carcinogens and cytostatic drugs induce different methylation products in DNA. In terms of cell-cycle arrest, p53 is not necessary for TMZ-induced G2-M arrest to occur, but is important in the duration of G2-M arrest (Hirose et al., 2001) . The relative contribution of MMR deficiency to cisplatin resistance remains unclear. According to Branch et al. (2000) , p53 status is a major determinant of cisplatin resistance and defective mismatch repair is a minor and independent contributor. Sansom and Clarke (2002) studied clonogenic survival in vivo following cisplatin treatment. The loss of Msh2 alone did not affect long-term cell survival, which was largely increased by the additional loss of p53. Clearly, further studies are indicated involving the sequential addition of other genetic lesions into the MEF system combined with appropriate temporal dissection of effects.
According to the dual checkpoint model for G2 arrest (Xu et al., 2002) , the MMR-associated early-acting delay may engage ATM-dependent pathways. Our results are in keeping with the finding that irradiation results in a reduced and shorter G2 arrest in MMRdeficient cells compared with proficient cells (Yan et al., 2001) , and that this functionally realizes through defective cdc2 signalling. The signal that is detected by the MMR protein complex is unknown, although there is some evidence that it is mediated by the regulation of c-jun NH 2 -terminal kinase 1, or c-Abl kinase (Nehme et al., 1999) . This could mean that MMR protein complex is not only involved in the repair of DNA damage, but also acts in transduction pathways that limit the replication of cells while DNA is damaged. Here we have confirmed that Msh2 À/À cells escaping G2 delay do not commit to early cell death and can therefore potentially form a reservoir from which abnormal clones may develop. Our observation of the second cycle, at least short-term, survival of cells traversing mitosis after cisplatin treatment, irrespective of Msh-2 status, suggests that neither mitotic catastrophe nor a rapid triggering of cell death are components of the early stress response. The findings suggest a model in which an MMR deficiency could provide a source for genetic variation through the premature generation through the premature generation of mitotic daughters.
It is becoming clear that abnormalities in G2/M arrest alone do not appear to confer sensitivity to DNA damage (Aquilina et al., 1999; Yan et al., 2001) .It has been suggested that cells could compensate for loss of a checkpoint through the initiation of a later checkpoint (Xu et al., 2002) , providing a complex contribution of sequential arrest responses to survival outcome. We suggest that it is reasonable to assume that the checkpoint status of the in vitro MEF cell system is near normal and that the effects observed relate to the impact of the Msh2 deficiency alone. Additionally, we can find no evidence of a prolonged mitosis, indicative of an activated spindle checkpoint in either untreated or cisplatin-exposed Msh2 À/À cells. In conclusion, we report on the loss of the early-acting phase of cycle arrest responses in G2 as a result of Msh2 loss without the generation of mitotic catastrophe or early cell death. We suggest that the premature commitment of Msh2 À/À cells carrying therapeutically induced or indeed constitutive unrepaired DNA damage into cell division, without an attendant triggering of cell death, may constitute a route to aneuploidy and genetic variation in daughter cells. The impact of this route would be greatest in the proliferating cellular compartments under physiological or oncogenic drivers.
